Press release
Psoriasis Pipeline Analysis, 2025 DelveInsight | Mylan, Biocad, Bristol-Myers Squibb, Celltrion, Coherus BioSciences, Janssen Pharmaceuticals, Can-Fite Biopharma, Arcutis Biotherapeutics, Amgen, Iltoo
Psoriasis Pipeline Analysis
According to DelveInsight, over 65 leading companies are actively developing more than 75 therapies targeting psoriasis, reflecting a robust and dynamic pipeline.
Psoriasis Overview:
Psoriasis is a chronic, immune-mediated skin disorder characterized by the rapid buildup of skin cells, leading to thick, red, scaly patches. It can affect any part of the body, commonly the elbows, knees, scalp, and lower back, and is often associated with itching, discomfort, and psychological stress. The disease can range from mild to severe and may be linked with comorbidities such as psoriatic arthritis, cardiovascular disease, and metabolic syndrome. While the exact cause is not fully understood, psoriasis involves an overactive immune response, particularly involving T-cells and inflammatory cytokines. Current treatments focus on topical therapies, phototherapy, systemic medications, and biologics, aimed at controlling symptoms and preventing flare-ups.
Download our report @ https://www.delveinsight.com/report-store/psoriasis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
"Psoriasis Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Psoriasis Therapeutics Market.
Key Takeaways from the Psoriasis Pipeline Report
*
DelveInsight's Psoriasis pipeline report depicts a robust space with 65+ active players working to develop 75+ pipeline therapies for Psoriasis treatment.
*
Key Psoriasis companies such as Can-Fite Biopharma, Huabo Biopharm Co., Ltd., MoonLake Immunotherapeutics, E-nitiate Biopharmaceuticals, Chia Tai Tianqing Pharmaceutical Group, BioRay Pharmaceutical Co., Ltd., SFA Therapeutics, Rubedo Life Sciences, Inc, and others are evaluating new drugs for Psoriasis to improve the treatment landscape.
*
Promising Psoriasis pipeline therapies in various stages of development include Piclidenoson, Sonelokimab, QY101, SFA 002, RLS-1496, and others.
Psoriasis Pipeline Analysis
The Psoriasis pipeline insights report 2025, provides insights into:
*
Provides comprehensive insights into key companies developing therapies in the Psoriasis Market.
*
Categorizes Psoriasis therapeutic companies by development stage: early, mid, and late-stage.
*
Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.
*
Reviews emerging Psoriasis drugs under development based on:
*
Stage of development
*
Psoriasis Route of administration
*
Target receptor
*
Monotherapy vs. combination therapy
*
Psoriasis Mechanism of action
*
Molecular type
*
Offers detailed analysis of:
*
Company-to-company and company-academia collaborations
*
Psoriasis Licensing agreements
*
Funding and investment activities supporting future Psoriasis market advancement.
Request for a sample report @ https://www.delveinsight.com/sample-request/psoriasis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Psoriasis Emerging Drugs
*
RLS-1496: Rubedo Life Sciences, Inc
*
SFA 002: SFA Therapeutics
*
QY101: E-nitiate Biopharmaceuticals
*
Sonelokimab: MoonLake Immunotherapeutics
*
Piclidenoson: Can-Fite Biopharma
Psoriasis Companies
Approximately 65+ leading companies are actively developing therapies for psoriasis. Among them, those with drug candidates in the most advanced stage (Phase III) include Can-Fite Biopharma.
DelveInsight's report covers around 80+ products under different phases of Psoriasis clinical trials like
*
Psoriasis Late stage Therapies (Phase III)
*
Psoriasis Mid-stage Therapies (Phase II)
*
Psoriasis Early-stage Therapies (Phase I)
*
Psoriasis Pre-clinical and Psoriasis Discovery stage Therapies
*
Psoriasis Discontinued & Inactive Therapies
Psoriasis pipeline report provides the Psoriasis therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
*
Intravenous
*
Subcutaneous
*
Oral
*
Intramuscular
Psoriasis Products have been categorized under various Molecule types such as
*
Monoclonal antibody
*
Small molecule
*
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Psoriasis Therapies and Key Psoriasis Companies: Psoriasis Clinical Trials and recent advancements https://www.delveinsight.com/report-store/psoriasis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Psoriasis Pipeline Therapeutic Assessment
- Psoriasis Assessment by Product Type
- Psoriasis By Stage
- Psoriasis Assessment by Route of Administration
- Psoriasis Assessment by Molecule Type
Download Psoriasis Sample report to know in detail about the Psoriasis treatment market @ Psoriasis Therapeutic Assessment [https://www.delveinsight.com/sample-request/psoriasis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Content
1. Report Introduction
2. Executive Summary
3. Psoriasis Current Treatment Patterns
4. Psoriasis - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Psoriasis Late-Stage Products (Phase-III)
7. Psoriasis Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Psoriasis Discontinued Products
13. Psoriasis Product Profiles
14. Psoriasis Key Companies
15. Psoriasis Key Products
16. Dormant and Discontinued Products
17. Psoriasis Unmet Needs
18. Psoriasis Future Perspectives
19. Psoriasis Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Psoriasis Pipeline Reports Offerings: https://www.delveinsight.com/report-store/psoriasis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=psoriasis-pipeline-analysis-2025-delveinsight-mylan-biocad-bristolmyers-squibb-celltrion-coherus-biosciences-janssen-pharmaceuticals-canfite-biopharma-arcutis-biotherapeutics-amgen-iltoo]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Psoriasis Pipeline Analysis, 2025 DelveInsight | Mylan, Biocad, Bristol-Myers Squibb, Celltrion, Coherus BioSciences, Janssen Pharmaceuticals, Can-Fite Biopharma, Arcutis Biotherapeutics, Amgen, Iltoo here
News-ID: 4170788 • Views: …
More Releases from ABNewswire
Phenix City Medical Practice Announces Expanded Healthcare Services, Addressing …
Preferred Medical Group, Phenix City, announces the expansion of its healthcare services and improved patient access, addressing community demand for comprehensive medical care with integrated pediatric, adult, and therapeutic services under one roof.
Preferred Medical Group, Phenix City [https://preferredmedgroup.com/], has announced significant enhancements to its healthcare services, responding to increased community demand for accessible and comprehensive medical care. The medical practice, located at 3700 South Railroad Street, has introduced streamlined patient…
Auburn Medical Practice Expands Integrated Care Model as Primary Care Doctor Add …
Preferred Medical Group - Auburn expands ADHD services and integrated care model, offering comprehensive family medicine, behavioral health, and specialized attention disorder treatment in one convenient East Alabama location.
Preferred Medical Group - Auburn [https://preferredmedgroup.com/] has announced significant enhancements to its integrated healthcare services, responding to increased demand for ADHD treatment and comprehensive family medical care in East Alabama. The Auburn location, situated at 318 Samford Village Court, Suite 100, now…
Local ADHD Doctor Program Launches at Preferred Medical Group - Opelika for East …
Preferred Medical Group - Opelika launches an integrated ADHD treatment program that combines pediatric care, psychiatry, and therapy services to address regional healthcare needs for East Alabama families.
Opelika healthcare providers have taken a significant step toward addressing the growing need for specialized attention deficit hyperactivity disorder services in East Alabama. Preferred Medical Group - Opelika [https://preferredmedgroup.com/] has announced the expansion of comprehensive ADHD treatment programs, integrating pediatric care with behavioral…
Prominent Criminal Lawyer in Galveston Firm Celebrates 25+ Years of Texas Gulf C …
Tad Nelson & Associates celebrates over 25 years of criminal defense excellence across the Texas Gulf Coast, combining local roots, community involvement, and personalized legal services that span multiple counties.
A prominent Texas law firm has reached a significant milestone, celebrating over 25 years of providing criminal defense and family law services across the Greater Houston area and Galveston County. The achievement underscores the firm's steadfast commitment to serving Texas communities…
More Releases for Psoriasis
Prevalence Of Psoriasis Driving Market Growth: A Key Catalyst Accelerating Psori …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Psoriasis Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
Over the recent years, there has been a robust growth in the size of the psoriasis market. It is estimated to rise from $26.45 billion in 2024 to $28.93 billion in 2025, with a compound annual…
Psoriasis Vulgaris Market
Introduction
Psoriasis vulgaris, also known as plaque psoriasis, is the most common form of psoriasis, accounting for nearly 80-90% of all cases. It is a chronic autoimmune condition marked by red, scaly plaques that can cause significant physical discomfort and emotional distress. Affecting millions worldwide, psoriasis vulgaris is increasingly recognized as both a dermatological and systemic disease due to its association with arthritis, cardiovascular disease, and metabolic syndrome.
The global psoriasis vulgaris…
Major Growth Driver Identified in 2025 Psoriasis Market: Prevalence Of Psoriasis …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Psoriasis Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
In recent times, the size of the psoriasis market has experienced a significant increase. It is projected to escalate from $26.56 billion in 2024 to $29.5 billion in 2025, reflecting a compound annual growth rate (CAGR)…
Prevalence Of Psoriasis Driving Market Growth: Key Factor Driving The Growth In …
The Psoriasis Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Psoriasis Market Size During the Forecast Period?
The psoriasis market has seen rapid growth in recent years. It will increase from $26.56 billion in 2024 to $29.5 billion in 2025, at a…
Plaque Psoriasis to Hold 85% Share of Psoriasis Drugs Market through 2031
Psoriasis is a chronic inflammatory skin disease that occurs due to genetic disposition and environmental factors. Psoriasis is a systemic disease associated with psychological, metabolic, arthritic, and cardiovascular comorbidities. On an average, psoriasis affects around 2 - 3% of the population globally.
Plaque psoriasis, being the number one and most common indication, held nearly 85% share of the US$ 11.37 Bn psoriasis drugs market in 2021, with the market estimated to…
Global Psoriasis Market with Focus on Plaque Psoriasis: Outlook to 2020
Psoriasis is a chronic inflammatory skin disease primarily causing scaling and inflammation of skin, characterized by sharply demarcated, scaly, red skin lesions most often on the elbows, knees, scalps, hands and feet. It occurs when the body’s immune system sends out faulty signals that speed up the growth cycle of skin cells. Psoriasis has been majorly classified into Plaque psoriasis, Guttate psoriasis, Inverse psoriasis, Pustular psoriasis and Erytherodermic psoriasis. It…
